Licenses and Supply Agreements (Details Narrative) - USD ($)				12 Months Ended
	Apr. 13, 2023	Jan. 19, 2023	Feb. 27, 2020	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2023	Mar. 26, 2023	Jun. 30, 2022
Interest payable				$ 152,315	$ 64,455
Cash payment description				In consideration for the license, the Company will provide (i) a non-refundable cash payment of $500,000 within ninety (90) days of September 30, 2022, (ii) a non-refundable cash payment of $500,000 at the earliest of either the National Agency for Food and Drug Administration and Control (“NAFDAC”) approval for JKB-122 in Africa for any indication, or the enrollment of the first patient in a Food and Drug Administration (“FDA”) trail for Crohn’s Disease, (iii) 250,000 shares of common stock of the Company within sixty (60) days of September 30, 2022, (iv) an annual payment of $100,000 each anniversary of the date of the agreement until the Company gains regulatory approval in Africa, (v) milestone payments (described below), and (vi) royalties on net sales. The 250,000 shares of common stock represent approximately 0.32% of the currently outstanding common stock of the Company.
Description for monthly interest for payment				the payment amount will bear the lower of (i) 1.5% interest per month or (ii) the maximum rate allowed by law, to be compounded quarterly. The interest will accrue beginning on the first day after the payment is due.
Balance of payments				$ 200,000			$ 150,000
Interest rate				6.00%
Common Stock [Member]
Number of shares issued					18,086,680
Sublicense Occurs Before Completing a Clinical Trial [Member]
Royalty percentage				30.00%
Sublicense Occurs After Completing a Clinical Trial [Member]
Royalty percentage				10.00%
Sublicense Occurs After Any New Drug Application (NDA) [Member]
Royalty percentage				5.00%
Less than 500,000,000 [Member]
Royalty Rate			2.00%			2.00%
From 500,000,000 to less than 1,000,000,000 [Member]
Royalty Rate			4.00%			4.00%
Greater than 1,000,000,000 [Member]
Royalty Rate			6.00%			6.00%
Board Of Directors [Member] | Common Stock [Member]
Number of shares issued, shares		250,000
Number of shares issued		$ 500,000
Taiwan J [Member]
Promissory notes	$ 250,000
Balance of payments	$ 100,000
Interest rate	18.00%
Maturity date description	matured on May 30, 2023
License Agreement [Member] | Forte Animal Health, Inc. [Member]
Non-refundable milestone payments			$ 100,000
Royalty term			15 years
Forte Animal Health, Inc. [Member]
Number of shares issued					2,235,000
Equity method investment, ownership percentage					15.00%
Forte Animal Health, Inc. [Member] | Amended License Agreement [Member]
Interest payable								$ 264,790
Forte Animal Health, Inc. [Member] | Amended License Agreement [Member] | Other Vendor And Employee [Member]
Interest payable								1,125,086
Forte Animal Health, Inc. [Member] | Amended License Agreement [Member] | Related Party [Member]
Promissory notes								$ 1,775,275